A study of a new device for type 2 diabetes and obesity
Part of Hormones & metabolism clinical trials.
This trial tests a device placed in the intestine to help control blood sugar and support weight loss in people with type 2 diabetes and obesity. It may offer a new option for managing both conditions together.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with type 2 diabetes and are obese.
- You can understand the study's purpose and give written consent.
- You are willing to follow all instructions after the procedure.
- You live within 100 kilometers (about 62 miles) of the study site.
- You are not pregnant and are not participating in another diabetes or metabolism study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (Eloralintide) to see if it can help with weight management. It is for people who have a body mass index (BMI) between 25 and 45 and stable weight.
This trial tests an investigational drug called GUB-UCN2 in people who are healthy, overweight, or have type 2 diabetes. The goal is to see if the drug is safe and how the body processes it.
This trial studies whether an endoscopic (camera-guided) stomach tightening/suturing procedure plus standard diabetes care can improve health in people with type 2 diabetes and mild-to-moderate obesity. It compares this procedure to standard care alone to see which approach works better and is safe.
This trial tests a procedure that reshapes the stomach and treats the upper intestine to help control blood sugar and weight in people with obesity and type 2 diabetes. It may be an option if you have a moderate to high need for metabolic surgery.
This study tests an implantable device called the RESET System that may help people with type 2 diabetes lose weight and improve blood sugar control. It is placed in the stomach without surgery and is for adults aged 22 to 65 who are overweight and have not had enough improvement with diabetes medications.
This study tests a combination of a fecal microbiota transplant (FMT), a calorie-restricted diet, and a type 2 diabetes medication (semaglutide) for people with obesity and recently diagnosed type 2 diabetes. The goal is to see if this approach can improve blood sugar control and weight loss.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.